Strategic partnerships for vascularized 3D tumour models in preclinical oncology

VoxCell is a Canadian biotechnology company seeking strategic partnerships with preclinical CROs, biopharma, and biotech companies to advance more predictive, human-relevant drug development in oncology.

VoxCell builds in vitro preclinical 3D vascularized human tumour tissue models designed to better recapitulate drug penetration, delivery, and tumour microenvironment effects than conventional 2D, spheroid, or organoid systems. Our tissues incorporate engineered, reproducible, perfusable vasculature, enabling controlled assessment of exposure, target engagement, immune infiltration, endothelial response, and vascular toxicity under physiologically relevant flow conditions.

We are particularly interested in partnerships where delivery biology is critical to interpretation, including biologics, ADCs, bispecifics, T cell engagers, and other advanced or immune-mediated modalities. Our goal is to help partners generate decision-grade datasets that improve early go or no-go decisions, sharpen candidate prioritization, and strengthen translational confidence.

We are actively seeking partnerships with:

• Preclinical CROs to integrate vascularized in vitro models into service offerings, validate NAM workflows, and build differentiated efficacy and safety packages

• Biopharma and biotech companies for focused pilot studies and collaborative therapeutic evaluation in a perfused, human-relevant tumour context

• Strategic partners to co-develop disease-specific tissue models with strong scientific rationale, market demand, and commercialization potential